Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Solid Tumors 1Recurrence 1Lymphoma, B-Cell 1Adenocarcinoma Pancreas 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Specimen Handling 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × selicrelumab × Clear all
NCT01103635 2020-04-07

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
25 enrolled
Dermatologic

Melanoma

NCT01008527 2015-09-24

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
22 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡